{
    "clinical_study": {
        "@rank": "142992", 
        "arm_group": [
            {
                "arm_group_label": "2 days placebo and 2 days drug", 
                "arm_group_type": "Experimental", 
                "description": "-"
            }, 
            {
                "arm_group_label": "1 day placebo and 3 days drug", 
                "arm_group_type": "Experimental", 
                "description": "-"
            }, 
            {
                "arm_group_label": "4 days placebo", 
                "arm_group_type": "Placebo Comparator"
            }, 
            {
                "arm_group_label": "4 days drug", 
                "arm_group_type": "Experimental", 
                "description": "-"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomised, double-blind, parallel groups, vehicle controlled, 8-week phase 2\n      trial. The objective is to evaluate efficacy of ingenol mebutate gel 0.06 % after once daily\n      treatment for 2, 3 or 4 consecutive days compared to vehicle gel"
        }, 
        "brief_title": "Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Actinic Keratosis", 
        "condition_browse": {
            "mesh_term": [
                "Keratosis", 
                "Keratosis, Actinic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Subjects with 5 to 20 clinically typical, visible and discrete AKs within a contiguous\n        area of approximately 250 cm\u00b2 sun-damaged skin on either trunk (except chest), or\n        extremities\n\n        Exclusion Criteria:\n\n          -  Location of the treatment area (trunk (except chest) or extremities)\n\n               -  within 5 cm of an incompletely healed wound,\n\n               -  within 5 cm of a suspected basal cell carcinoma (BCC) or squamous cell carcinoma\n                  (SCC)\n\n          -  Prior treatment with ingenol mebutate within the selected treatment area\n\n          -  Lesions in the treatment area that have:\n\n               -  atypical clinical appearance (e.g., hypertrophic,hyperkeratotic or cutaneous\n                  horns) and/or,\n\n               -  recalcitrant disease (e.g., did not respond to cryotherapy on two previous\n                  occasions)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "240", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01998984", 
            "org_study_id": "LP0105-1020"
        }, 
        "intervention": {
            "arm_group_label": [
                "2 days placebo and 2 days drug", 
                "1 day placebo and 3 days drug", 
                "4 days drug"
            ], 
            "intervention_name": "ingenol mebutate", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "last_name": "Daniel M Siegel, MD MS"
            }, 
            "facility": {
                "address": {
                    "city": "Smithtown", 
                    "country": "United States", 
                    "state": "New York"
                }, 
                "name": "Long Island Skin Cancer and Dermatologic Surgery"
            }, 
            "investigator": {
                "last_name": "Daniel M Siegel, MD MS", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "4", 
        "official_title": "Efficacy and Safety of Ingenol Mebutate Gel 0.06% When Applied Once Daily for 2, 3 or 4 Consecutive Days to a Treatment Area of Approximately 250 cm2 on Trunk and Extremities in Subjects With Actinic Keratosis", 
        "overall_contact": {
            "email": "mette.kielsholm@leo-pharma.com", 
            "last_name": "Mette K Fife, MSc", 
            "phone": "+45 72262445"
        }, 
        "overall_official": {
            "affiliation": "Lond Island Skin Cancer and Dermatologic Surgery", 
            "last_name": "Daniel M Siegel, MD, MS", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate efficacy of ingenol mebutate gel after once daily treatment for 2, 3 or 4 consecutive days compared to vehicle gel", 
            "measure": "Complete clearance of AKs", 
            "safety_issue": "No", 
            "time_frame": "Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01998984"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Reduction in AK count", 
                "safety_issue": "No", 
                "time_frame": "From baseline to week 8"
            }, 
            {
                "measure": "Partial clearance of AKs", 
                "safety_issue": "No", 
                "time_frame": "From baseline to week 8"
            }
        ], 
        "source": "LEO Pharma", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "LEO Pharma", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}